tosufloxacin has been researched along with Infections, Salmonella in 3 studies
tosufloxacin: quinolone anti-infective agent; structure given in first source
tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.
7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the purpose of evaluation of clinical efficacy, safety and usefulness on Salmonella enteritis, T-3262 (Tosufloxacin tosilate), a newly developed pyridone-carboxylic acid derivative, was administered to a total of 103 patients and carriers." | 9.06 | [Clinical trial of T-3262 (Tosufloxacin tosilate) on Salmonella enteritis, and fecal drug concentration and change in the fecal microflora in the acute diarrheal patients. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis]. ( Aoki, T; Kamimura, M; Kanehisa, N; Matsubara, Y; Nitia, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I, 1989) |
| "Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy." | 7.71 | Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001) |
| "For the purpose of evaluation of clinical efficacy, safety and usefulness on Salmonella enteritis, T-3262 (Tosufloxacin tosilate), a newly developed pyridone-carboxylic acid derivative, was administered to a total of 103 patients and carriers." | 5.06 | [Clinical trial of T-3262 (Tosufloxacin tosilate) on Salmonella enteritis, and fecal drug concentration and change in the fecal microflora in the acute diarrheal patients. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis]. ( Aoki, T; Kamimura, M; Kanehisa, N; Matsubara, Y; Nitia, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I, 1989) |
| "Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy." | 3.71 | Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Obana, M | 1 |
| Ohnishi, K | 1 |
| Kimura, K | 1 |
| Aoki, T | 1 |
| Matsubara, Y | 1 |
| Sagara, H | 1 |
| Shimizu, N | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Nitia, Y | 1 |
| Seo, T | 1 |
| Kamimura, M | 1 |
| Kanehisa, N | 1 |
1 review available for tosufloxacin and Infections, Salmonella
| Article | Year |
|---|---|
[Salmonella infections].
Topics: 4-Quinolones; Anti-Infective Agents; Fluoroquinolones; Gastroenteritis; Humans; Naphthyridines; Prog | 2003 |
1 trial available for tosufloxacin and Infections, Salmonella
| Article | Year |
|---|---|
[Clinical trial of T-3262 (Tosufloxacin tosilate) on Salmonella enteritis, and fecal drug concentration and change in the fecal microflora in the acute diarrheal patients. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
Topics: 4-Quinolones; Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Diarrhea; Enteritis; Fec | 1989 |
1 other study available for tosufloxacin and Infections, Salmonella
| Article | Year |
|---|---|
Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Enterocolitis; Feces; Female; | 2001 |